CINECA IRIS Institutional Research Information System

BOCCACCINO, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.258
AS - Asia 823
EU - Europa 630
SA - Sud America 122
AF - Africa 50
OC - Oceania 1
Totale 2.884
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.231
SG - Singapore 322
IT - Italia 268
CN - Cina 215
HK - Hong Kong 147
BR - Brasile 101
DE - Germania 74
SE - Svezia 62
GB - Regno Unito 57
FI - Finlandia 33
FR - Francia 32
BG - Bulgaria 28
VN - Vietnam 25
CI - Costa d'Avorio 23
IN - India 19
JP - Giappone 19
CA - Canada 14
KR - Corea 14
PL - Polonia 14
NL - Olanda 12
AR - Argentina 11
ID - Indonesia 11
RU - Federazione Russa 11
MX - Messico 10
NG - Nigeria 9
TR - Turchia 9
ES - Italia 7
UA - Ucraina 7
BD - Bangladesh 6
SN - Senegal 6
IQ - Iraq 5
LT - Lituania 5
PK - Pakistan 5
CZ - Repubblica Ceca 4
AT - Austria 3
IE - Irlanda 3
MY - Malesia 3
TH - Thailandia 3
AM - Armenia 2
AO - Angola 2
CL - Cile 2
CO - Colombia 2
EG - Egitto 2
IR - Iran 2
JO - Giordania 2
KG - Kirghizistan 2
KH - Cambogia 2
MA - Marocco 2
PE - Perù 2
PH - Filippine 2
PS - Palestinian Territory 2
PT - Portogallo 2
VE - Venezuela 2
AL - Albania 1
AZ - Azerbaigian 1
BF - Burkina Faso 1
CR - Costa Rica 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
GT - Guatemala 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
KE - Kenya 1
KW - Kuwait 1
LB - Libano 1
LY - Libia 1
MT - Malta 1
NA - Namibia 1
NZ - Nuova Zelanda 1
RO - Romania 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TN - Tunisia 1
UY - Uruguay 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 2.884
Salva come PNG Salva come JPEG
Città #
Dallas 193
Ashburn 183
Singapore 176
Hong Kong 142
Santa Clara 127
Chandler 81
Fairfield 70
Shanghai 55
New York 45
Florence 43
Wilmington 40
London 39
Munich 39
Los Angeles 38
Boardman 35
Seattle 35
Beijing 31
Pisa 31
Sofia 28
Cambridge 27
Abidjan 23
Woodbridge 22
Hefei 21
Cascina 18
Turku 18
Princeton 17
Lawrence 16
Tokyo 16
Helsinki 15
Ogden 14
Seoul 14
Bremen 13
Frankfurt am Main 13
Genoa 13
Warsaw 13
Medford 12
São Paulo 12
Turin 12
Redondo Beach 11
Houston 10
Serra 10
Ho Chi Minh City 9
Lagos 9
Milan 9
Rome 9
Ann Arbor 8
Buffalo 6
Dakar 6
Denver 6
Istanbul 6
Orem 6
Quanzhou 6
San Diego 6
Verona 6
Kent 5
Phoenix 5
Seacroft 5
Baghdad 4
Brooklyn 4
Fuzhou 4
Karachi 4
Montreal 4
Ottawa 4
Polverigi 4
Redwood City 4
Washington 4
Coreglia Antelminelli 3
Curitiba 3
Dhaka 3
Dublin 3
Düsseldorf 3
Fortaleza 3
Gargallo 3
Hanoi 3
Jakarta 3
Mexico City 3
Mumbai 3
Olomouc 3
Pistoia 3
Porto Alegre 3
Portsmouth 3
Qingdao 3
Querétaro 3
Stockholm 3
Tangerang 3
Toronto 3
Vienna 3
Amman 2
Amsterdam 2
Anzio 2
Aracaju 2
Atlanta 2
Augusta 2
Bangkok 2
Bari 2
Bergamo 2
Bexley 2
Bishkek 2
Bologna 2
Boston 2
Totale 2.003
Salva come PNG Salva come JPEG
Nome #
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis 172
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial 158
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable 154
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component 147
TRIPLETE: A randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer 144
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver Metastases 142
AtezoTRIBE: A randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer 137
Primary tumour side as a driver for treatment choice in RAS wild-type metastatic colorectal cancer patients: a systematic review and pooled analysis of randomised trials 135
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study 131
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 121
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies 118
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study 117
FOLFOXIRI and bevacizumab in patients with early-onset metastatic colorectal cancer. A pooled analysis of TRIBE and TRIBE2 studies 111
TK-1, TP, Ang-2, and Tie-2 mRNA expression in plasma-derived microvesicles of chemo-refractory metastatic colorectal cancer patients 109
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest 102
Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials 91
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 90
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: A pooled analysis of TRIBE and TRIBE2 studies 90
Treatments after second progression in metastatic colorectal cancer: A pooled analysis of the TRIBE and TRIBE2 studies 89
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature 88
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer 85
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience 83
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial 80
null 65
Treatment of patients with BRAFV600E-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 61
Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study 60
Prognostic and Predictive Role of Body Mass Index (BMI) in Metastatic Colorectal Cancer (mCRC): A Pooled Analisys of Tribe and Tribe-2 Studies by GONO 53
null 15
Totale 2.948
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.830
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.830
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021102 0 0 0 0 0 42 2 6 13 5 12 22
2021/2022132 1 0 2 0 21 24 2 5 5 16 16 40
2022/2023340 25 51 20 24 33 33 17 20 56 2 50 9
2023/2024302 11 24 39 33 34 42 22 14 5 14 39 25
2024/20251.085 36 41 28 62 87 137 75 49 119 97 125 229
2025/2026806 124 160 169 110 159 84 0 0 0 0 0 0
Totale 2.948